FDA Investigator Charlotte P Chang
Charlotte P Chang has conducted inspections on 49 sites in 2 countries as of 29 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
49
Last Inspection Date:
29 May 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
United Kingdom of Great Britain and Northern Ireland
FDA Investigators that have inspected at least one site in common with Charlotte P Chang:
Amy L Singer,
Annemarie Bodnar,
Annet R Rajan,
Antoinette L Ravelli,
Barbara J Maulfair,
Bryan A Galvez,
Burnsb,
Carol A Perry,
Carol A Robles,
Cary Greene,
Cathleen A Carr Sharpe,
Christina K Theodorou,
David M Wilkinson,
Dawn L Wydner,
Dena M Elimam,
Dhaval H Patel,
Doreen P Canetti,
Doreen P Gubbay,
Dyana K Stone,
Edward O'shaughnessy,
Edwin J Gorney,
Eric R Holm,
Eric Rothschild,
Gabriel E Muniz,
Garciam,
Gianine E Delade,
Gianine E Tompkins,
Helen B Ricalde,
Helen Verdel,
Jay B Shah,
Jessica M Monteiro,
Jill Mielziner,
Joseph T Dougherty,
Judy C Nepsa,
Justin A Boyd,
Justine Tomasso,
Karen A Spencer,
Karen F Tomaziefski,
Keith M Reilly,
Kelli F Dobilas,
Kelly Doremus,
Kevin K Cole,
Kristy A Zielny,
Krystal O Ogunremi,
Kyle D Covill,
Lata C Mathew, PhD,
Lawrence R Johnson,
LCDR Angelica M Chica,
Li Li,
Lisa B Hall,
Marjorie D Schultz,
Melissa B Libby,
Omayra Nrodriguez Ruiz,
Paul L Bellamy,
Raymond L Cheung,
Regina T Brown,
Remache,
Richard D Manney,
Robin P Mathew,
Rodrigo Vilchez,
Schultz,
Sherri J Liu,
Shirley S Wen,
Sinai I Davis,
Siramad Sainz Trujillo,
Sparky L Bartee,
Stephanie T Durso,
Susan M Halsted,
Suzanne A Lovelady,
Valerie C Reed,
Vashti E Bocker,
Zachary P Wachlarowicz
Charlotte P Chang's Documents
Publish Date | Document Type | Title |
---|---|---|
July, 2023 | FDA 483 | Aspire Pharmaceuticals Inc. - Form 483, 2023-07-14 |
February, 2022 | FDA 483 | SHUZY ROCK INC - Form 483, 2022-02-14 |
February, 2022 | FDA 483 | Aspire Pharmaceuticals Inc. - Form 483, 2022-02-03 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more